Erratum  by unknown
ERRATAIn ‘‘The Role of Cytotoxic Therapy with Hemato-
poietic StemCell Transplantation in the Treatment of
Pediatric Acute Lymphoblastic Leukemia: Update of
the 2005 Evidence-Based Review’’ [Hahn et al., Biol
Blood Marrow Transplant 2012:18:505-522] in the
abstract, the acronym ‘‘MRD’’ in the second to the
last sentence should be expanded to ‘‘minimal residual
disease’’ to read ‘‘Based on expert opinion, allogeneic
SCT may be considered for hypodiploid ALL andIn ‘‘Comparison of Outcomes after HLA-Matched
Sibling and Unrelated Donor Transplantation for
Children with High-Risk Acute Lymphoblastic Leu-
kemia’’ [Thiel et al., Biol Blood Marrow Transplant
2012:18:1204-1210], the author Elizabeth L. Thiel
was inadvertently excluded from the author list.
1466persistent minimal residual disease (MRD) positivity
in ALL in CR1 or greater, although these are areas
that need further study.’’
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